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Radiation esophagitis is a serious complication occurring in patients receiving radiotherapy for head and neck cancers. Current
treatment with proton pump inhibitors and mucosal protectants provides symptomatic relief with few studies showing improvement in erosive esophagitis or ulceration. Use of self-expandable metal stents (SEMS) in cases of erosive radiation
esophagitis refractory to medical therapy has not been studied. We report a case of a patient presenting with recurrent
hematemesis from late (chronic) radiation esophagitis with bleeding esophageal ulceration successfully treated with SEMS
placement after failure of conservative medical management, proposing a possible utility for SEMS in this setting.

1. Introduction
Late (chronic) radiation esophagitis occurs after three
months of radiation therapy completion presenting with
stricture or dysmotility-related dysphagia and rarely with the
feared complication of tracheoesophageal ﬁstula or esophageal perforation [1]. Increasing edema and inﬂammation
beyond 30 days of radiation therapy eventually leads to
stricture formation as the esophagus loses its distensibility
[2]. On the other hand, symptomatic acute radiation
esophagitis is a rare complication occurring in <1% of
patients receiving radiation for lymphoma, lung, head, and
neck cancers [3, 4]. It typically occurs 2-3 weeks after radiation therapy and presents with odynophagia, dysphagia,
and less likely with hematemesis [4]. The mainstay treatment
of radiation-related esophageal strictures is endoscopic dilation and use of proton pump inhibitor therapy [1]. The
mainstay treatment for acute radiation esophagitis includes
dietary modiﬁcation in the form of eliminating irritants such
as spicy foods and conforming to soft foods [4]. In addition,
medical therapy with proton pump inhibitors (PPI), histamine blockers, and mucosal protectants such as sucralfate
are eﬀective in promoting healing [4]. We report a case of
self-expandable metal stent (SEMS) use for the treatment of

recurrent hematemesis in a patient with late (chronic) radiation esophagitis refractory to medical therapy. Additionally, we discuss the management of radiation esophagitis
and consideration for SEMS placement to promote mucosal
healing by luminal exclusion.
1.1. Case. A 59-year-old Caucasian male with a history of
stage IVA squamous cell carcinoma of the left mandible by
TNM classiﬁcation [5] presented with 1 day of hematemesis.
His malignancy was diagnosed 2 years prior and treated by
surgical resection followed by neoadjuvant chemoradiotherapy. His neoadjuvant regimen constituted of cisplatin, a total of 7200 cGy radiation dose (200 cGy/fraction
with 36 fractions) to the left retromolar trigone and 6480 cGy
radiation dose (180 cGy/fraction with 36 fractions) to the
right neck. Recurrence 8 months prior to presentation
prompted repeat radiation therapy performed at an outside
institution, and hence, the retreatment protocol is not
known. He had received supplemental enteral nutrition
through endoscopic percutaneous gastrostomy tube for 2
years. He denied worsening dysphagia or odynophagia.
Routine laboratory tests demonstrated a hemoglobin level of
9.7 g/dl (laboratory normal: 13.5–17 g/dl).
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Figure 1: (a) Endoscopic appearance of distal esophagus demonstrating esophageal ulcer with active oozing (blue arrow). (b) Endoscopic
appearance of distal esophagus following fully covered self-expanding metal stent (SEMS) (WallFlex Esophageal Stents, Boston Scientiﬁc,
Marlborough, MA) deployment.
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Intravenous pantoprazole 40 mg twice daily was started,
and esophagogastroduodenoscopy (EGD) was performed
revealing diﬀuse erosive esophagitis and mild gastritis with
no ulceration. No further bleeding ensued, and the patient
was discharged home on omeprazole 40 mg twice daily. He
presented 5 months later with hematemesis, and a repeat
EGD demonstrated a cratered 10 mm oozing esophageal
ulcer at 33 cm from the incisors in a background of severe
radiation esophagitis in the entire esophagus (grade 3 by
Kuwahata’s score [6]) (Figure 1(a)). Given the location of the
lesion, active bleeding, and the lack of improvement with
outpatient PPI therapy, a fully covered 23 × 105 mm SEMS
(WallFlex Esophageal Stents, Boston Scientiﬁc, Marlborough, MA) was deployed to achieve hemostasis
(Figure 1(b)). The patient was discharged only to return in 2
months with recurrent hematemesis. An abdominal radiograph demonstrated stent migration into the stomach
(Figure 2(a)), and a repeat EGD was performed with stent
removal. The cratered ulcer had completely healed at that
time, but a background of diﬀuse severe esophagitis persisted (Figure 2(b)). Another identical stent was deployed.
No further bleeding occurred, and he was discharged home
with plans for replacement in 4 weeks.
Given diﬃculties accessing the hospital during the novel
coronavirus (COVID-19) pandemic, he did not present for
stent replacement and presented 5 months later with abdominal pain and was found to have recurrent stent migration. EGD demonstrated residual diﬀuse circumferential
esophagitis, and the stent was removed. He continues to take
omeprazole 40 mg twice daily. Liquid sucralfate 1 g four
times daily was added to his regimen. He had no bleeding
recurrence on follow-up 5 months later.
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2. Discussion
Achieving tumor control via radiotherapy without damage
to adjacent tissues is diﬃcult. Acute radiation esophagitis
occurs in patients undergoing treatment for head and neck
cancers. It occurs 2-3 weeks after the ﬁrst treatment and can
occur as late as 6 months to 1 year [7]. Patients often present

with dysphagia, odynophagia, and substernal pain [7].
Esophageal stricture is a late complication that occurs 6–8
months after the ﬁrst treatment dose and is a result of
continual mucosal inﬂammation and ﬁbrosis [7]. In addition, life-threatening complications such as perforation and
ﬁstulas can occur rendering early treatment of radiation
esophagitis crucial [7].
Current mainstay prevention and treatment of radiation
esophagitis includes diet modiﬁcation to soft and bland diets
[4]. Proton pump inhibitors (PPI), histamine blockers,
antacids, and sucralfate are also used. However, use of these
agents in patients with acute radiation esophagitis has
yielded conﬂicting results. Sur et al. showed resolution of
dysphagia and odynophagia along with improved ulcer
healing time in patients receiving sucralfate compared with
ones receiving antacids within 7 days of treatment [8], while
another study showed no diﬀerence compared with placebo
[9]. The use of free-radical neutralizing agents like amifostine may help relieve symptoms such as dysphagia. A
prospective study demonstrated reduced esophagitis rates
with use of prophylactic agents like glutamine [4].
The use of SEMS in radiation esophagitis is usually
preserved for the treatment of symptomatic ﬁbrotic benign
strictures when dilations fail to relieve symptoms and/or
luminal narrowing [10, 11]. Studies evaluating the role of
SEMS for esophageal ulceration with or without associated
bleeding in radiation esophagitis are lacking. SEMS has been
utilized in the control of esophageal variceal hemorrhage
and is thought to control bleeding by a combination of
tamponade and luminal exclusion promoting mucosal
healing with success rates of 93.9% in a meta-analysis and a
rebleeding rate of 13.2% [11–13]. In the reported case, a
similar mechanism likely contributed to the resolution of the
ulcer in 3 months following the ﬁrst stent placement.
Stent migration remains a major concern with esophageal stenting and occurred twice in the reported case. In
patients receiving SEMS for malignant dysphagia, stent
migrations have been reported in 15.4% of patients, with
higher risks in patients receiving fully covered SEMS, at
25.3% [14]. Endoscopic suturing or stent clipping to the
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Figure 2: (a) Computed tomography (CT) of the abdomen demonstrating migration of self-expanding metal stent (SEMS) into the stomach
(blue arrow). (b) Endoscopic appearance of distal esophagus demonstrating ulcer healing but with residual diﬀuse radiation esophagitis.
Table 1: Methodological appraisal of the reported case using the
Murad tool [18] for risk of bias assessment of case reports and case
series.
Gill et al.

Q1i
Yes

Q2ii
Yes

Q3iii
Yes

Q4iv
Yes

Q5v
Yes

Q6vi
Yes

i, does the patient represent the whole experience of the investigator? ii, was
the diagnosis adequately ascertained? iii, was the outcome adequately
ascertained? iv, were other alternative causes that may explain the observation ruled out? v, was follow-up long enough for outcomes to occur? vi, is
the case(s) described with suﬃcient details to allow other investigators to
replicate the research or to allow practitioners maker inferences related to
their own practice?

postulate the possible use of SEMS as salvage therapy when
conservative measures fail in treatment of bleeding secondary to late radiation esophagitis. A methodological appraisal of our case report using the Murad tool [18] is
summarized in Table 1.
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esophageal wall are options that could be utilized to reduce
risks of stent migration and in retrospect should have
probably been utilized in this case [15, 16]. Studies where
SEMS were utilized for controlling variceal bleeding stent
migration occurred in 21.6% in a meta-analysis [13] and in
38% in another case series [12]. The need for repeat endoscopy and stent removal adds to the overall morbidity and
cost of utilizing SEMS in this setting. Concerns regarding
tissue embedding following SEMS placement are uncommon in fully covered stents such as the one used [11].
Another important consideration is the risk of stent erosion
particularly at the area of ulceration and formation of a
tracheoesophageal or bronchoesophageal ﬁstula requiring
possible surgical repair [17]. In the reported case, we utilized
a fully covered SEMS to promote mucosal healing, and
tamponade bleeding in a patient with late (chronic) radiation esophagitis refractory to medical therapy. Migration of
the SEMS into the stomach likely resulted in the rebleeding
of the exposed friable mucosa leading to recurrent hematemesis. However, ulcer healing was observed, and no interval bleeding had occurred until stent migration ensued.
Therapeutic measures for radiation esophagitis are limited,
and untreated esophagitis leads to ulceration, ﬁstula formation, perforations, and structure formation [4]. We
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